In this episode: What the FDA warning really means for Wegovy, Ozempic, and Zepbound users Why an OAI classification matters — and how it could affect GLP-1 access How the FDA oversight system protects patients (and where it fails) Why compounded GLP-1 medications exist in the first place The bigger picture: access, safety, and patient rights